Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings

Movement Disorders

Volumn 31, Issue 2, 2016, Pages 250-256

  Adler, Charles H ^a   Dugger, Brittany N ^b   Hentz, Joseph G ^a   Hinni, Michael L ^a   Lott, David G ^a   Driver Dunckley, Erika ^a   Mehta, Shyamal ^a   Serrano, Geidy ^b   Sue, Lucia I ^b   Duffy, Amy ^a   Intorcia, Anthony ^b   Filon, Jessica ^b   Pullen, Joel ^b   Walker, Douglas G ^b,c   Beach, Thomas G ^b  

^a MAYO CLINIC   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

biopsy; Parkinson's disease; submandibular gland; synuclein

Indexed keywords

ALPHA SYNUCLEIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORE BIOPSY NEEDLE; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DRAIN; FALSE POSITIVE RESULT; FEMALE; GLAND TISSUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MALE; NEEDLE BIOPSY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SKIN BRUISING; SORE THROAT; SUBMANDIBULAR GLAND; SWELLING; SYNUCLEINOPATHY; METABOLISM; MIDDLE AGED;

AGED; ALPHA-SYNUCLEIN; BIOPSY, NEEDLE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBMANDIBULAR GLAND;

EID: 84958073264     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26476     Document Type: Article

References (25)

1. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689–702.
2. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease?. Evidence from 3 cases. Mov Disord 2012;27:717–719.
3. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709–715.
4. Visanji NP, Marras C, Kern DS, et al. Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015;84:609–616.
5. Tolosa E, Vilas D. Peripheral synuclein tissue markers: a step closer to Parkinson's disease diagnosis. Brain 2015;138:2114–2152.
6. Miki Y, Tomiyama M, Ueno T, et al. Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. Neurosci Lett 2010;469:357–359.
7. Donadio V, Incensi A, Leta V, et al. Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014;82:1362–1369.
8. Rodriguez-Leyva I, Calderon-Garciduenas AL, Jimenez-Capdeville ME, et al. alpha-Synuclein inclusions in the skin of Parkinson's disease and parkinsonism. Ann Clin Transl Neurol 2014;1:471–478.
9. Wang N, Gibbons CH, Lafo J, Freeman R. α-Synuclein in cutaneous autonomic nerves. Neurology 2013;81:1604–1610.
10. Zange L, Noack C, Hahn K, Stenzel W, Lipp A. Phosphorylated a-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain 2015;138:2310–2321.
11. Beach TG, Adler CH, Dugger BN, et al.; Arizona Parkinson's Disease Consortium. Submandibular gland biopsy for the diagnosis of Parkinson's disease. J Neuropathol Exp Neurol 2013;72:130–136.
12. Adler CH, Dugger BN, Hinni ML, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson's disease. Neurology 2014;82:858–864.
13. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014;83:406–412.
14. Stern MB, Doty RL, Dotti M, et al. Olfactory function in Parkinson's disease subtypes. Neurology 1994;44:266–268.
15. Beach TG, White CL, Hamilton RL, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008;116:277–288.
16. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160–164.
17. Walker DG, Lue LF, Adler CH, et al.; Arizona Parkinson Disease Consortium. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol 2013;240:190–204.
18. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119:703–713.
19. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613–634.
20. Driver-Dunckley E, Adler CH, Hentz JG, et al.; Arizona Parkinson Disease Consortium. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease. Parkinsonism Relat Disord 2014;20:1260–1262.
21. Postuma RB. Prodromal Parkinson's disease—using REM sleep behavior disorder as a window. Parkinsonism Relat Disord 2014;20(Suppl 1):S1–S4.
22. Ba F, Martin WR. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord 2015;21:87–94.
23. Stoessl AJ, Halliday GM. DAT-SPECT diagnoses dopamine depletion, but not PD. Mov Disord 2014;29:1705–1706.
24. Perju-Dumbrava LD, Kovacs GG, Pirker S, et al. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. Mov Disord 2012;27:65–71.
25. Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 2014;29:1767–1773.